# Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

> **NCT05489328** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 394 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **OTHER:** Candidate-1
- **OTHER:** Candidate-2
- **OTHER:** Candidate-3
- **OTHER:** Candidate-4
- **OTHER:** Candidate-5
- **OTHER:** Candidate-6
- **OTHER:** Candidate Control
- **BIOLOGICAL:** 13vPnC
- **BIOLOGICAL:** PCV15

## Key facts

- **NCT ID:** NCT05489328
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2022-10-07
- **Final completion:** 2022-10-07
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489328, "Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05489328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*